A statin cut heart attacks and strokes by 30 percent in healthy people over 70

Cholesterol-lowering drugs are usually prescribed after something has already gone wrong with a person’s heart, not before. A large clinical trial is challenging that pattern by testing what happens when healthy people well into their seventies start taking a statin before any cardiovascular event occurs, and the results suggest the drug’s benefits extend further into older age than the standard prescribing habits assume. The findings arrive at a moment when doctors and patients alike are re-examining long-held assumptions about when preventive medication stops paying off.

Inside the STAREE Trial’s Older, Healthier Population

Researchers behind the trial tested atorvastatin specifically in older adults who had not yet experienced a heart attack, stroke or other major cardiovascular event, a population that is often excluded from statin-focused research because most cardiovascular drug trials recruit patients who already have diagnosed disease. Studying a healthy older cohort instead let researchers isolate the drug’s effect as genuine primary prevention, rather than as treatment layered on top of existing heart damage.

The 30 Percent Drop in Major Cardiovascular Events

Participants taking the statin saw major cardiovascular events occur in 6.0% of cases, compared with 8.3% among those not on the drug, a reduction described by Monash University researchers as roughly 30 percent. That gap, measured across a large trial population, is large enough to represent a meaningful number of heart attacks and strokes prevented rather than a marginal statistical difference that could plausibly be explained by chance. For a drug class that has been in wide clinical use for decades, a 30 percent relative reduction in a previously understudied age group is a substantial addition to the existing evidence base rather than an incremental tweak.

The gap between 6.0% and 8.3% may look modest at first glance, but the comparison is measuring the same underlying population over the same follow-up period, differing only in whether they received the statin. Translated across a trial large enough to detect that kind of difference reliably, it represents a meaningful number of major cardiovascular events, the kind involving hospitalization, long-term disability or death, that occurred in the untreated group but did not occur in the treated one.

Why Age Alone Has Discouraged Preventive Statin Use

Clinical guidance has historically been cautious about starting statins purely for prevention in people over 70, partly because most of the supporting trial evidence for statins was generated in younger and middle-aged populations, and partly because older patients carry a different balance of risks and benefits, including a higher baseline likelihood of other health conditions that complicate any medication decision. That caution has meant many otherwise healthy people in their seventies and beyond have not been offered a statin purely as a preventive measure, even though their absolute risk of a first heart attack or stroke rises with age.

The trial’s design directly targets that gap by asking not whether statins help people who already have heart disease, but whether starting the drug before any event occurs still pays off once someone is already well into their seventies. The 30 percent reduction suggests the answer is yes, at least for the population and dosing studied.

That question carries particular weight because the population studied, healthy adults over 70 with no prior cardiovascular event, grows every year as life expectancy extends and more people spend a longer stretch of old age without having already had a heart attack or stroke. A trial answering whether preventive treatment still helps that specific group speaks directly to a segment of the population that existing statin guidance, built mostly on younger trial participants, was never designed to address with confidence.

What the Findings Could Mean for Prescribing Guidance

Because the reduction was measured against a genuine placebo-style comparison rather than against a different drug, the results speak directly to whether starting a statin later in life, in someone with no prior cardiovascular event, is worth the trade-offs of a new long-term medication. Any change to prescribing guidelines based on results like these would need to weigh the demonstrated reduction in heart attacks and strokes against statins’ known side-effect profile in an older population, a judgment that sits with physicians and guideline committees rather than with the trial data alone.

What the trial does establish is that age above 70, on its own, is not evidence that a statin has stopped being useful as prevention. For a drug already taken by tens of millions of people worldwide, extending the demonstrated benefit further into older adulthood changes the calculus for a specific, previously underserved group: people who are currently healthy, currently untreated, and currently aging past the point where most of the existing statin evidence was generated.

It also reframes a conversation that often defaults to treating advanced age as a reason to scale medications back rather than add new ones, sometimes described as deprescribing. The STAREE results do not argue against that broader instinct in general, but they do suggest that blanket caution about starting a statin purely because of a patient’s age, absent other complicating health conditions, deserves a second look grounded in trial evidence rather than assumption.

This article was produced with AI assistance and edited by Morning Overview staff.

More from Morning Overview